Patient P-02326
Synthetic patientMETA-24 · Day 171 · 35–44 · M · baseline S18Steering view · 3DOpen companion preview
Therapy response
Declining
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
90%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S18
- Day 47 NP-02 recommended — Dietary Support Protocol NP-02
- Day 48 Patient accepted — Started NP-02 in the companion
- Day 58 GI symptom burden −18% vs expected — Dietary Support Protocol NP-02
- Day 64 Tolerance state changed — Unstable → Improving
- Day 70 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 72 SC-12 recommended — Supportive Compound SC-12
- Day 73 Patient accepted — Started SC-12 in the companion
- Day 78 GI-04 recommended — GI Support Protocol GI-04
- Day 79 Patient declined — Not now
- Day 79 GI symptom burden −14% vs expected — Supportive Compound SC-12
- Day 85 Tolerance state changed — Unstable → Improving
- Day 89 ME-01 recommended — Monitoring Escalation ME-01
- Day 90 Patient accepted — Started ME-01 in the companion
- Day 93 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 70.
Primary contributors, last 14 days
- Toxicity+14
- Treatment adherence-9
- Nutritional resilience-6
- GI instability+4
- Inflammatory activity+3
What helped?
- Dietary Support Protocol NP-02Day 47Result: symptom burden −18%
- Supportive Compound SC-12Day 72Result: symptom burden −14%
- GI Support Protocol GI-04Day 78Declined by patient
- Monitoring Escalation ME-01Day 89Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
87%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 88% showed improvement
- median effect visible after 8 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable44 min
worsening · -3.3 vs previous 14 d
Sleep duration
Wearable6.2 h
improving · +0.2 vs previous 14 d
Energy level
Daily log2.1/10
improving · +0.5 vs previous 14 d
Steps
Wearable4,616
worsening · -274 vs previous 14 d
GI burden
Companion59.2/100
improving · -2.6 vs previous 14 d
Adherence
Companion40 %
worsening · -5.5 vs previous 14 d
Sleep quality
Wearable39/100
improving · +4.0 vs previous 14 d
Glucose, CGM daily mean
CGM138 mg/dL
stable · -3.4 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 25 from the failing basin, 64 from restoration.
Would help
- GI-04 GI Support Protocol75% improved among 65 similar · onset 8 d · confidence 86%
- CR-01 Clinician Review100% improved among 6 similar · onset 5 d · confidence 71%
- DT-01 Dosing / Timing Recommendation67% improved among 6 similar · onset 5 d · confidence 71%
- More proteinGI -6.8 next day on high-intake days · n 19
Would not help
- Keep fat lowGI +6.9 next day on high-intake days · n 25
- Keep ultra-processed lowGI +6.2 next day on high-intake days · n 26
- Keep simple carbs lowGI +5.5 next day on high-intake days · n 22
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Dietary fat load+6.9detractor · 95%
- Protein-6.8supporter · 95%
- Ultra-processed food+6.2detractor · 95%
- Simple carbohydrates+5.5detractor · 95%
- Histamine load+5.1detractor · 95%
- Insoluble fibre-0.5no signal · 15%
- Alcohol+0.5no signal · 15%
- Caffeine+0.4no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 39/100
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓50
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 59 and rising
- Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 57
- Autonomic recovery ↓45
- WearableResting HR 74 bpm
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 55
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Intermediate metabolizerExpected exposure
Microbiome
Shannon diversity 1.9 · butyrate capacity 39/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 49 ms
- Sleep
- 6.1 h
- Steps
- 3,602
- Resting HR
- 75 bpm
Daily log: GI score 59, nutritional resilience 38, adherence 40.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02670 | 51% | S14 | SC-12 | improved | 45 |
| P-02018 | 50% | S01 | GI-04 | improved | 46 |
| P-02234 | 50% | S14 | GI-04 | improved | 36 |
| P-02059 | 49% | S03 | SC-12 | improved | 41 |
| P-02316 | 49% | S14 | GI-04 | improved | 51 |
| P-02516 | 49% | S14 | SC-12 | improved | 51 |
| P-02535 | 49% | S14 | SC-12 | improved | 50 |
| P-02106 | 48% | S14 | GI-04 | improved | 44 |
| P-02348 | 48% | S14 | GI-04 | improved | 49 |
| P-02401 | 47% | S14 | GI-04 | improved | 49 |
| P-02002 | 46% | S14 | GI-04 | improved | 47 |
| P-02103 | 46% | S14 | GI-04 | improved | 46 |